The CD52 antigen and development of the CAMPATH antibodies

Cytotherapy. 2001;3(3):137-43. doi: 10.1080/146532401753174098.
No abstract available

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Animals
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD / immunology
  • Antigens, Neoplasm / immunology
  • CD52 Antigen
  • Drug Design
  • Glycoproteins / antagonists & inhibitors*
  • Glycoproteins / immunology
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / prevention & control*
  • Humans
  • Immunosuppression / adverse effects
  • Immunosuppression / methods*
  • Infections / chemically induced
  • Infections / immunology
  • Infections / physiopathology
  • Lymphocytes / drug effects*
  • Lymphocytes / immunology
  • Male
  • Mammals / immunology
  • Rats
  • Spermatozoa / immunology
  • Stem Cell Transplantation / adverse effects*
  • Stem Cell Transplantation / methods
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Cd52 protein, rat
  • Glycoproteins
  • Alemtuzumab